Elevance Health stock analysis
Elevance Health (A58) Stock Price & Analysis
A58 Stock Chart & Stats
- Day’s Range
- CHF 369.86 - CHF 369.86
- 52-Week Range
- CHF 346.20 - CHF 369.86
- Previous Close
- CHF 369.86
- Volume
- N/A
- Average Volume (3M)
- 1
- Market Cap
- CHF 70.85B
- Enterprise Value
- CHF 115.48B
- Total Cash (Recent Filing)
- CHF 37.85B
- Total Debt (Recent Filing)
- CHF 30.76B
- Price to Earnings (P/E)
- 16.8
- Beta
- -0.34
- Next Earnings
- Jan 27, 2027 (Est.)
- EPS Estimate
- 1.76
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.48%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Elevance’s strong cash conversion provides internal funding for investments, capital returns, and balance-sheet needs. The $6.5 billion TTM free-cash-flow recovery indicates substantial earnings support, although continued monitoring is warranted because cash conversion has varied across years.
Carelon Growth Platform
Carelon broadens Elevance beyond traditional insurance risk through healthcare services sold to affiliated and external customers. New wins, high retention, and a broad pipeline can diversify revenue, deepen customer relationships, and support longer-term operating leverage.
Large Membership Scale
A membership base of nearly 45 million creates scale across networks, claims administration, pharmacy, and care-management capabilities. Commercial fee-based growth also supports revenue diversification while reducing reliance on any single government-sponsored membership category.
Bears Say
Margin Compression
Persistent margin compression reduces the earnings benefit of revenue growth and leaves less room for adverse medical-cost or pricing developments. Lower operating profitability also makes execution in Medicaid, Medicare Advantage, and commercial products more important to sustained returns.
Elevated Medical Cost Trends
When reimbursement rates lag underlying care costs, health-plan margins can remain pressured even when membership and premium revenue grow. Elevance expects improvement, but the timing depends on rate alignment and successful medical-cost actions across affected businesses.
Moderate-to-Elevated Leverage
Moderate-to-elevated leverage can constrain financial flexibility when operating margins are under pressure. It may limit the capacity to absorb weaker underwriting results or pursue investments while also increasing the importance of maintaining strong, predictable cash generation.
Elevance Health News
A58 FAQ
What was Elevance Health’s price range in the past 12 months?
What is Elevance Health’s market cap?
When is Elevance Health’s upcoming earnings report date?
How were Elevance Health’s earnings last quarter?
Is Elevance Health overvalued?
Does Elevance Health pay dividends?
What is Elevance Health’s EPS estimate?
How many shares outstanding does Elevance Health have?
What happened to Elevance Health’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Elevance Health?
What is the TipRanks Smart Score and how is it calculated?
Elevance Health Stock Smart Score
Company Description
Elevance Health
Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- CEO
- Gail Koziara Boudreaux
- Employees
- 96,615
- Website
- www.elevancehealth.com
- Address
- 220 Virginia Avenue, Indianapolis, IN, 46204, US
Elevance Health (A58) Earnings & Revenues
A58 Company Deck
A58 Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Elevance Health reported better-than-expected third-quarter results, raised 2026 adjusted EPS guidance to at least $29, increased its earnings baseline to at least $26.75, raised operating cash flow guidance to at least $6.5 billion, and maintained confidence in at least 12% adjusted EPS growth in 2027. Medicaid cost trends, commercial cost pressures, IDR-related issues, ACA risk-pool normalization, and a non-recurring fourth-quarter tax item remain challenges, but management characterized operating performance and visibility as improving across the enterprise.
View all CH:A58 earnings summaries











